Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by Sir_Holleron Jun 20, 2015 9:20am
174 Views
Post# 23851598

RNAi

RNAiFor advancing RNAi in the liver, though not through Phase III yet, ALNY's market capitalization hit a record C$14.5 billion on Friday. Piper put a C$18.5 billion target price on it this week.

Being the first to deliver to the brain of a living animal with therapeutic effect, when will BTI publish the details of its stroke results in a scientific peer review journal? Sketchy results were released over 3 months ago in a news release. BTI also paid for an analyst report and announced the reports release to shareholders in a news release. The analyst report expected BTI to commence human trials this year. BTI has said that it was aggressivly pursuing human clinical trials. In a presentation BTI also had ALS on its agenda. The stroke study was undertaken to support licensing.

Published RNAi results(first proof in living animals for efficacy),
Published results with Herceptin,
Published Lysosomal Storage Disease results,
Commencement of human testing for all three.
Deals on Herceptin, RNAi...
Commencement of human testing.



Bullboard Posts